Zhang Jian G, Hepburn Lucy, Cruz Gabriela, Borman Richard A, Clark Kenneth L
Pharmagene Laboratories Limited, 2 Orchard Road, Royston SG8 5HD, UK.
Biochem Pharmacol. 2005 Mar 15;69(6):883-9. doi: 10.1016/j.bcp.2004.12.008.
Adenosine is an endogenous nucleoside that regulates many physiological processes through the activation of its four receptors: A(1), A(2A), A(2B) and A(3). Previous studies have identified the involvement of A(2) receptors in the inhibitory activity of adenosine analogues on tumor necrosis factor-alpha (TNF-alpha) production by lipopolysaccharide (LPS) activated monocytes, but the relative contributions of A(2A) versus A(2B) receptors have not been determined in human primary monocytes. Nor has the role of A(1) and A(3) been clearly identified in the system. The lack of such information impacts on the selection of adenosine receptor agonists for disease intervention. Using LPS-stimulated human primary monocytes, we found that the adenosine receptor agonist, 5'-N-ethylcarboxamidoadenosine (NECA) or the A(2A) receptor agonist, 4-[2-[[6-amino-9-(N-ethyl-b-d-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid hydrochloride (CGS21680) produced a concentration-dependent inhibition of TNF-alpha production, with IC(50)s of 58.4nM (32.7-104.5nM, 95% confidence interval) and 49.2nM (22.7-105.9nM, 95% confidence interval), respectively. The selective A(2A) receptor blocker, 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylaminso]ethyl)phenol (ZM241385, 30nM), antagonized the effects of NECA and CGS21680 (pK(B) estimates were 8.7+/-0.1 and 8.9+/-0.1, respectively), while the selective A(2B) antagonist, N-(4-cyano-phenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-2,3,4,5,6,7-hexahydro-1H-purin-8-yl)-phenoxy]-acetamide (MRS1754, 100nM), failed to antagonize the effects of either agonist. Furthermore, neither the A(1) receptor agonist, 2-chloro-N(6)-cyclopentyladenosine (CCPA) nor the A(3) receptor agonist, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-b-d-ribofuranuronamide (2-Cl-IB-MECA) showed significant inhibitory activity at concentrations that effectively bind to their respective receptors. We conclude that A(2A) receptor activation is predominantly responsible for the inhibitory effects of adenosine receptor agonists on TNF-alpha production from LPS-stimulated monocytes.
腺苷是一种内源性核苷,它通过激活其四种受体:A(1)、A(2A)、A(2B)和A(3)来调节许多生理过程。先前的研究已确定A(2)受体参与腺苷类似物对脂多糖(LPS)激活的单核细胞产生肿瘤坏死因子-α(TNF-α)的抑制活性,但在人原代单核细胞中,A(2A)与A(2B)受体的相对贡献尚未确定。在该系统中,A(1)和A(3)的作用也尚未明确。此类信息的缺失影响了用于疾病干预的腺苷受体激动剂的选择。使用LPS刺激的人原代单核细胞,我们发现腺苷受体激动剂5'-N-乙基羧基酰胺腺苷(NECA)或A(2A)受体激动剂4-[2-[[6-氨基-9-(N-乙基-β-D-呋喃核糖酰胺基)-9H-嘌呤-2-基]氨基]乙基]苯丙酸盐酸盐(CGS21680)产生浓度依赖性的TNF-α产生抑制作用,IC(50)分别为58.4nM(32.7 - 104.5nM,95%置信区间)和49.2nM(22.7 - 105.9nM,95%置信区间)。选择性A(2A)受体阻滞剂4-(2-[7-氨基-2-(2-呋喃基)[1,2,4]三唑并[2,3-a][1,3,5]三嗪-5-基氨基]乙基)苯酚(ZM241385,30nM)拮抗了NECA和CGS21680的作用(pK(B)估计值分别为8.7±0.1和8.9±0.1),而选择性A(2B)拮抗剂N-(4-氰基苯基)-2-[4-(2,6-二氧代-1,3-二丙基-2,3,4,5,6,7-六氢-1H-嘌呤-8-基)-苯氧基]-乙酰胺(MRS1754,100nM)未能拮抗任何一种激动剂的作用。此外,A(1)受体激动剂2-氯-N(6)-环戊基腺苷(CCPA)和A(3)受体激动剂1-[2-氯-6-[[(3-碘苯基)甲基]氨基]-9H-嘌呤-9-基]-1-脱氧-N-甲基-β-D-呋喃核糖酰胺(2-Cl-IB-MECA)在有效结合其各自受体的浓度下均未显示出显著的抑制活性。我们得出结论,A(2A)受体激活主要负责腺苷受体激动剂对LPS刺激的单核细胞产生TNF-α的抑制作用。